SUMIT: Selumetinib in metastatic uveal melanoma (with Paul Nathan)
Released Monday, 24th June 2019
Good episode? Give it some love!
SUMIT: Selumetinib in metastatic uveal melanoma (with Paul Nathan)
SUMIT: Selumetinib in metastatic uveal melanoma (with Paul Nathan)
Monday, 24th June 2019
Good episode? Give it some love!
Rate Episode
Advisory Board member and study author Paul Nathan, from the Mount Vernon Cancer Centre in Middlesex, UK, discusses the phase III SUMIT trial, which evaluated the addition of the MEK inhibitor selumetinib to dacarbazine in patients with metastatic uveal melanoma.
Find more on Medicine Matters oncology
This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on May 4, 2018.
Show More
Rate
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Episode Tags
Do you host or manage this podcast?
Claim and edit this page to your liking.
,Claim and edit this page to your liking.
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us